Sugi Predict

Sugi Predict / Compounds / SCHEMBL230177

SCHEMBL230177

SCHEMBL230177

FC(F)(F)c1ccnc(N2CCNCC2)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ADRB1 P08588 2/20 1.00
▸ RBP4 P02753 1/20 0.54
▸ HTR2C P28335 5/20 0.52
▸ HTR2A P28223 4/20 0.52
▸ HTR2B P41595 4/20 0.52
▸ KDM4E B2RXH2 2/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ PKM P14618 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ SLC6A7 Q99884 1/20 0.50
▸ OGA O60502 1/20 0.49
▸ EPHX2 P34913 1/20 0.48
▸ PARP1 P09874 1/20 0.47
▸ ACHE P22303 2/20 0.47
▸ CA12 O43570 1/20 0.46
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ CA9 Q16790 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL17541669 0.98 ADRB1 (0.97) ADRB1RBP4HTR2CHTR2AHTR2B
SCHEMBL2005654 0.94 ADRB1 (0.89) ADRB1RBP4HTR2CHTR2AHTR2B
SCHEMBL8354208 0.88 ADRB1 (0.78) ADRB1RBP4HTR2CHTR2AHTR2B
SCHEMBL28070992 0.85 ADRB1 (0.73) ADRB1RBP4HTR2CHTR2AHTR2B
SCHEMBL11916019 0.84 ADRB1 (0.72) ADRB1HTR2CKDM4EALDH1A1ACHE
SCHEMBL13286847 0.83 ADRB1 (0.71) ADRB1RBP4HTR2CHTR2AHTR2B
SCHEMBL3556451 0.83 ADRB1 (0.71) ADRB1RBP4HTR2CHTR2AHTR2B
SCHEMBL16655537 0.83 ADRB1 (0.70) ADRB1RBP4HTR2CKDM4EALDH1A1
SCHEMBL1999765 0.82 ADRB1 (0.69) ADRB1RBP4HTR2CHTR2AHTR2B
SCHEMBL31024025 0.82 ADRB1 (0.68) ADRB1RBP4HTR2CKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118084874-B Thickened oil viscosity-reducing oil displacement agent and synthesis method thereof 胜利油田方圆化工有限公司 2024-07-09 — — CN claimed
CN-118084874-A Thickened oil viscosity-reducing oil displacement agent and synthesis method thereof 胜利油田方圆化工有限公司 2024-05-28 — — CN claimed
US-20140273458-A1 Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-18 — — US claimed
EP-2779217-A2 Chemical mechanical planarization for tungsten-containing substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-17 — — EP claimed
EP-1204645-A2 MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF Millennium Pharmaceuticals, Inc. (US) 2002-05-15 — — EP claimed
WO-2001010842-A2 MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2001-02-15 — — WO claimed
WO-2024165050-A1 PROTEOLYSIS-TARGETING CHIMERA (PROTAC) COMPOUNDS AND USES THEREOF FIELD AUBRAK THERAPEUTICS (CN) 2024-08-15 — — WO disclosed
CN-115745971-B PARP7 inhibitor and application thereof 北京华森英诺生物科技有限公司 2024-07-30 — — CN disclosed
CN-118084874-B Thickened oil viscosity-reducing oil displacement agent and synthesis method thereof 胜利油田方圆化工有限公司 2024-07-09 — — CN disclosed
CN-118084874-B Thickened oil viscosity-reducing oil displacement agent and synthesis method thereof 胜利油田方圆化工有限公司 2024-07-09 — — CN disclosed
CN-118084874-A Thickened oil viscosity-reducing oil displacement agent and synthesis method thereof 胜利油田方圆化工有限公司 2024-05-28 — — CN disclosed
CN-118084874-A Thickened oil viscosity-reducing oil displacement agent and synthesis method thereof 胜利油田方圆化工有限公司 2024-05-28 — — CN disclosed
US-11851435-B2 PTGR2 inhibitors and their use NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2023-12-26 — — US disclosed
WO-2002062766-A2 MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-08-15 — — WO disclosed
EP-1204645-A2 MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF Millennium Pharmaceuticals, Inc. (US) 2002-05-15 — — EP disclosed
WO-2001010842-A2 MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2001-02-15 — — WO disclosed
US-5977106-A 3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives PIERRE FABRE MEDICAMENT (FR) 1999-11-02 — — US disclosed
EP-0794949-B1 NOVEL 3,5-DIOXO-(2H,4H)-1,2,4-TRIAZINE DERIVATIVES, THEIR PREPARATION AND USE AS DRUGS PF MEDICAMENT (FR) 1998-07-29 — — EP disclosed
EP-0794949-A1 NOVEL 3,5-DIOXO-(2H,4H)-1,2,4-TRIAZINE DERIVATIVES, THEIR PREPARATION AND USE AS DRUGS PIERRE FABRE MEDICAMENT (FR) 1997-09-17 — — EP disclosed
WO-1996016949-A1 NOVEL 3,5-DIOXO-(2H,4H)-1,2,4-TRIAZINE DERIVATIVES, THEIR PREPARATION AND USE AS DRUGS PIERRE FABRE MEDICAMENT (FR) 1996-06-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11851435-B2 PTGR2 inhibitors and their use PTGFR, PTGIR, PTGDR2 ADRB1 128/4885RBP4 4411/4885HTR2C 341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.